Clinical Trial Update: Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) [Phase 2]

View source ↗

Summary

The ENESTop Phase 2 trial reports treatment-free remission after achieving sustained deep molecular response (MR4.5) in chronic myeloid leukemia patients treate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2021-01-13